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Malaria: Dissecting chloroquine resistance
Robert G. Ridley
The malaria parasite’s development of resistance to the
drug chloroquine is a major threat to world health. A
protein likely to be involved in chloroquine resistance
has recently been identified; this discovery is important,
but raises as many questions as it answers.
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The malaria parasite, Plasmodium falciparum, has, through
its invasion and destruction of red blood cells, been a
source of disease and a scourge of human civilisation since
the earliest times. Malaria is among the most significant
sources of global disease burden, causing approximately
two million deaths each year, primarily in young children
and pregnant women. The drug chloroquine, since its
availability in the late 1940s, has been the mainstay of
efforts to treat and control the disease. The value of
chloroquine has resided in its efficacy, its relative safety at
prescribed clinical doses, and its low cost. Furthermore,
compared to other drugs, such as the anti-folate
pyrimethamine, resistance to chloroquine has been rela-
tively slow to develop [1]. 
Resistance to chloroquine has, however, steadily spread
since the 1960s from two foci, one in South America and
one in South East Asia. Throughout the 1980s, chloro-
quine resistance spread through Africa, the global heart-
land of malaria mortality and morbidity, and there are very
few effective and affordable drugs to take its place. A
better understanding of the nature of this resistance could
help us design better drugs in the future, and a recent
article by Su et al. [2] opens a new door to understanding
the nature of chloroquine resistance. Here, I shall build on
several recent reviews on the mechanism of chloroquine
activity and resistance [3–7], and attempt to put the new
findings into the context of our current understanding of
chloroquine resistance development. 
Chloroquine’s mechanism of action
Many theories have been expounded to explain
chloroquine’s mode of action [3–5]. These have included
DNA binding and the inhibition of a variety of enzymes
and/or transporters. For the purpose of this article,
however, I shall assume that the antimalarial effect of
chloroquine results from its concentration to high levels in
the acidic lysosomal food vacuole of the parasite and its
binding to haematin [5] (Figure 1). The food vacuole is the
site of haemoglobin degradation in the parasite, and
iron (II) haem is released as a by-product [8]. Under normal
circumstances, the iron (II) haem is oxidised to iron (III)
haematin and sequestered into a polymer of β-haematin as
an inert pigment called haemozoin. By binding to
haematin, chloroquine is believed to disrupt this process,
and it has been demonstrated that free haematin or chloro-
quine–haematin complexes are membrane interactive and
potentially toxic to the parasite (see [4,5] for references).
Further confirmation that haematin is the receptor for
chloroquine comes from studies using the compound
Ro 40-4388, a specific inhibitor of haemoglobin proteoly-
sis. This compound inhibits an aspartic protease, plas-
mepsin 1, which is believed to initiate proteolysis of
haemoglobin in the food vacuole [9]. The inhibitor there-
fore effectively prevents haem release from haemoglobin.
In its presence, the activity of chloroquine is antagonised
[9] and the number of chloroquine binding sites in the
parasite is significantly reduced [10]. Haematin binding
therefore appears to be required both for chloroquine to
exert its activity on the parasite and for its concentration in
the food vacuole. 
Chloroquine resistance and drug accumulation
Another aspect of chloroquine activity that has received a
lot of attention is how the drug gets to the food vacuole to
enable it to interact with haematin. Figure 1 shows how
many membranes chloroquine has to cross to reach
haematin in the food vacuole. Drug transport is believed
to be of crucial importance for understanding the mecha-
nism(s) of chloroquine resistance, as it is clear that less
chloroquine accumulates in chloroquine-resistant parasites
than in chloroquine-sensitive parasites [6,7]. It was
originally thought that this lack of accumulation was the
result of an efflux mechanism, and a P-glycoprotein was
implicated as the pump responsible for the efflux. Subse-
quent studies, however, have suggested that efflux rates
of chloroquine-resistant and chloroquine-sensitive strains
are similar. It now appears that chloroquine resistance
involves a diminished level of drug uptake, rather than, or
as well as, enhanced efflux.
There are a number of possible causes of reduced
chloroquine uptake. It could result, for example, from
altered pH gradients across the food vacuole membrane or
between the parasite cytosol and the erythrocyte cytosol;
from an alteration in membrane permeability or in the
specificity of a permease or other transporter; or from an
alteration in some molecule — such as a protein associated
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with haematin in the food vacuole — that compromises
haematin’s accessibility to the drug. Significantly, only
minor changes in chloroquine’s structure, such as varying
the 4-aminoalkyl side-chain’s length by one carbon atom,
can yield compounds with good activity against chloro-
quine-resistant strains [11]. This implies a high degree of
structural specificity in the factors responsible for reduced
chloroquine uptake, consistent with the involvement of
either a specific permease/transporter or a molecule associ-
ated with heamatin in the food vacuole.
A number of compounds — such as the so-called
chloroquine-resistance-reversal agents verapamil, desipra-
mine and chlorpheniramine — are capable of specifically
enhancing the activity of chloroquine against chloroquine-
resistant strains [6,7]. Their mechanism(s) of action are
unclear, though they appear to work by enhancing chloro-
quine uptake by the parasite. Interestingly, studies with
verapamil suggest that, although it enhances chloroquine
uptake in resistant strains, chloroquine levels still do not
reach those found in sensitive strains. This suggests that
more than one mechanism may contribute to chloroquine
uptake and chloroquine resistance [6,7]. Also, there are a
series of quinolines that are active against moderately
chloroquine-resistant strains, but are less active against
highly chloroquine-resistant strains [11]. For some of these
compounds, the activity against highly chloroquine-resis-
tant strains can be further enhanced by desipramine, while
for others, it cannot (C. Jaquet, personal communication).
This suggests that there are two mechanisms by which such
quinolines bypass chloroquine resistance, one of which is
desipramine-associated and the other of which is not.
The precise mechanism of chloroquine uptake remains
unknown. It has recently been suggested that chloroquine
enters the parasite by a Na+/H+ exchanger [12]. This idea
is based on saturation kinetics, and the fact that amiloride
derivatives, inhibitors of mammalian Na+/H+ exchangers,
inhibit chloroquine uptake by the parasite. No parasite
Na+/H+ exchanger has yet been identified to allow more
detailed studies, so whether this hypothesis is true
remains an open question. The saturation kinetics were
measured using intact parasites and thus do not constitute
proof of a specific chloroquine transporter, as they could
equally well reflect the binding of chloroquine to another
receptor, such as haematin. Also, it is difficult to envisage
chloroquine substituting for Na+ in a transporter system. It
has recently been demonstrated that replacement of Na+
in the culture medium by other cations, such as choline or
glucamine, does not result in enhanced chloroquine
uptake, contrary to what one would expect if chloroquine
competes with sodium for uptake [10]. 
An alternative explanation of the inhibitory activity of
amiloride derivatives is that uptake of chloroquine, a weak
base, obliges the parasite to equilibrate a variety of intra-
cellular and intercellular pH gradients. One potentially
significant way of achieving this is through the Na+/H+
exchanger, and its inhibition would therefore prevent
further chloroquine uptake. A consequence of this alterna-
tive hypothesis would be that chloroquine itself would
stimulate Na+/H+ exchange activity, which is indeed the
case [12]. A Na+/H+ exchanger could thus be essential for
the parasite, but it need not necessarily play a primary role
in chloroquine uptake; instead, the exchanger could play a
secondary role of maintaining cellular pH subsequent to
chloroquine uptake. 
It may be difficult to prove the direct involvement of a
specific permease or transporter in chloroquine uptake.
Indeed, one could postulate that no specific transporters
are required and that chloroquine crosses the necessary
membranes into the food vacuole by diffusion, driven
primarily by concentration gradients, pH gradients and its
binding to haematin.
Genetic basis of chloroquine resistance
While many investigators have studied the biochemistry
of drug uptake in the hope of getting a handle on the
mechanism of chloroquine resistance, and others have
Figure 1
Schematic representation of a mature malaria parasite growing within
an erythrocyte. The diagram emphasises the major membrane barriers
that need to be crossed by chloroquine to access the food vacuole,
which is the site of haemoglobin degradation, haem release and
haematin polymerisation. Chloroquine is believed to exert its activity by
binding to haematin. Chloroquine is concentrated from nanomolar
levels outside the parasite to millimolar levels in the food vacuole. Hb,
haemoglobin; Hz, haemozoin; cg2, product of the polymorphic,
chloroquine-resistance-associated cg2 gene; [CQ]i, chloroquine
concentration inside parasite food vacuole; [CQ]o, external chloroquine
concentration. (The localisation of cg2 is taken from [2].)
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sought insights from correlations involving the sequences
and expression levels of specific genes, Wellems and col-
leagues [2,13] have taken a genetic approach. They
crossed chloroquine-resistant and chloroquine-sensitive P.
falciparum clones, passaging the parasites through a mos-
quito, where sexual replication occurs, and collecting
progeny from a subsequently infected chimpanzee [13].
Initial analysis of the progeny showed that chloroquine
resistance segregated at one locus, a region of chromo-
some 7 not corresponding to any gene encoding a P-glyco-
protein homologue. The data suggested that resistance
might be caused by mutations in a single gene. It was
hoped that identification of this locus would provide the
missing link in the chloroquine-resistance story. Recently,
the locus was mapped to within 36 kilobases (kb). The
leading candidate gene from within this region is cg2,
though other genes in the 36 kb region cannot be entirely
ruled out [2]. Newly developed transfection techniques
may enable final clarification of this issue. 
The cg2 gene turns out to encode a highly polymorphic
protein, in keeping with early ideas that multiple muta-
tions are required to generate chloroquine resistance.
Immunogold electron microscopy showed that the cg2
protein is located at both the parasitophorous vacuole, the
space separating the parasite from the erythrocyte host
cell, and the food vacuole, the proposed site of chloro-
quine–haematin interaction [2]. It has been postulated
that the cg2 protein may actually be an integral membrane
Na+/H+ exchanger [14], but this is highly speculative and
is not consistent with other lines of evidence from bio-
chemical and localization experiments (T.E. Wellems,
personal communication).
One particular cg2 polymorphism correlates very well with
chloroquine resistance, and segregates with resistance in
the original genetic cross experiment. When a large
number of parasite isolates were sequenced from South-
East Asia and Africa, however, one clone from Sudan was
found which had the polymorphism normally associated
with a chloroquine-resistance phenotype, but it was actu-
ally chloroquine sensitive. The cg2 polymorphism thus
appears to be necessary, but not sufficient, for chloroquine
resistance, again consistent with the view that chloroquine
resistance is a multi-gene phenomenon. We still need to
identify the other gene(s) responsible. 
From the data available so far, there is no genetic link to
suggest an involvement of P-glycoprotein homologues,
though there is some biochemical evidence that proteins
of this type are involved in chloroquine transport [6]. A
possible next step would be to cross the aberrant
Sudanese chloroquine-sensitive strain with the chloro-
quine-resistant strain used in the initial genetic cross
experiment, to see how chloroquine resistance segregates
amongst the progeny. With the efficient DNA sequencing
techniques now available it is possible that any loci that
are identified could be much more rapidly characterised
than in the first cross.
In the absence of such genetic information, and with no
clear sequence similarities between cg2 and any known
protein, we are left to speculate on the nature of chloro-
quine uptake into the food vacuole and on the role that
cg2 plays for the parasite and in chloroquine resistance. It
is possible that, with the identification of cg2, we might
again be looking at a secondary, albeit important, aspect of
chloroquine resistance, and that we are still missing a key
factor. If we assume that chloroquine resistance is a multi-
gene event, then one could imagine that the key mutation
that causes chloroquine resistance — for example, by
affecting chloroquine transport and/or sequestration in the
food vacuole — only works fully when it occurs against a
genotypic background that includes specific cg2 alleles, of
the type identified by Wellems and colleagues. 
The location of the cg2 gene product suggests it is secreted
into the parasitophorous vacuole, or perhaps resides as a
parasite surface protein, and is later taken up into vesicles
which fuse with the food vacuole, presumably by some
endocytotic process. What could its function be? One
possibility is that it could itself be intimately involved in
the haemoglobin degradation/haematin polymerisation
process. Another is that it could help transport other mol-
ecules to the food vacuole for this or other purposes, such
as the relief of oxidative stress brought about by the oxida-
tion of iron (II) haem to iron (III) haematin. Clearly, a
broad range of possibilities exist.
It is worth noting that a further level of complication may
yet arise in the search for chloroquine-resistance
mechanisms. Su et al. [2] report that chloroquine
resistance stems from two loci, one in South East Asia and
one in South America. Their paper concentrates on strains
from South East Asia, but it transpires that the cg2 allele of
chloroquine-resistant South American isolates differs from
that of the chloroquine-resistant South East Asian isolates
(T.E. Wellems, personal communication). By analogy with
the development of resistance to other antimicrobial
agents, such as β-lactam antibiotics, one should not be too
surprised if different mechanisms predominate in differ-
ent geographical locations. 
In some ways, the identification and characterisation of the
cg2 gene product [2] have raised more questions than they
have answered about the nature of chloroquine resistance.
One feels, however, that this protein, possibly along with
others encoded within the 36 kb genomic region associated
with chloroquine resistance, is likely to play a crucial role
for the parasite, and that we are on the verge of gaining
valuable insights into key parasite processes associated
with parasite haemoglobin degradation and chloroquine
resistance. More focused experimental approaches can now
be taken to determine the genetic and biochemical basis of
chloroquine resistance.
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